The Scientist

» pharma

Most Recent

image: Legionnaires’ Bacteria at GSK

Legionnaires’ Bacteria at GSK

By | August 14, 2015

GlaxoSmithKline temporarily shuts down a manufacturing plant in North Carolina after Legionella bacteria are detected in two external cooling towers.

0 Comments

image: Teva Buys Allergan Generics for $40.5 Billion

Teva Buys Allergan Generics for $40.5 Billion

By | July 27, 2015

Meanwhile, Allergan acquires drug developer Naurex in a $560 million deal. 

0 Comments

image: Biotech Buys Autoimmune Firm for $7B

Biotech Buys Autoimmune Firm for $7B

By | July 16, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

4 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Roche Set to Buy RNAi Firm

Roche Set to Buy RNAi Firm

By | August 6, 2014

The Swiss pharmaceutical giant will reportedly pay $450 million for a Danish biotech company that develops drugs that silence microRNAs.

2 Comments

image: EMA Gearing Up for Transparency

EMA Gearing Up for Transparency

By | June 16, 2014

The European Medicines Agency is preparing for a new policy that will release rarely-seen clinical trial reports for independent scrutiny.  

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Mutation Linked to Longer Life Span in Men
  4. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

AAAS